Erythematotelangiectatic Rosacea Clinical Trial
Official title:
Randomized, Double-Blind, Parallel-Group, Vehicle-Controlled, Dose-Finding Study Investigating the Pharmacodynamics and Safety of Three Concentrations of CD07805/47 Topical Gel (0.07%, 0.18%, and 0.50%), Applied in Subjects With Moderate to Severe Erythematotelangiectatic Rosacea
Verified date | September 2013 |
Source | Galderma R&D |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This is a randomized, double-blind, parallel-group, vehicle-controlled, dose-finding study to investigate the pharmacodynamics and the safety of three dosages of CD07805/47 topical gel (0.07%, 0.18%, and 0.50%), after a single application in subjects with a clinical diagnosis of stable moderate to severe erythematotelangiectatic rosacea. Subjects will be randomized in a 1:1:1:1 ratio to receive either one of three CD07805/47 topical gel concentrations (0.07%, 0.18%, or 0.50%) or Vehicle Gel. All subjects will be treated with a single application (once daily dosing for one day) of study medication.
Status | Completed |
Enrollment | 122 |
Est. completion date | December 2009 |
Est. primary completion date | November 2009 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Male or female who is at least 18 years of age. - Clinical diagnosis of stable moderate to severe erythematotelangiectatic rosacea. - CEA (clinician's erythema assessment) score greater than or equal to 3 at Screening and on Treatment visit at baseline. - PSA (patient self assessment) score of greater than or equal to 3 at Screening and on Treatment visit at baseline. - Presence of 2 or fewer inflammatory facial lesions. Exclusion Criteria: - History of Raynaud's Syndrome, glaucoma, orthostatic hypotension, thromboangiitis obliterans, cerebral or coronary insufficiency, or depression. - History of refractive surgery such as photorefractive keratectomy. - The subject is being treated with monoamine oxidase (MAO) inhibitor, anti-depressants, barbiturates, opiates, sedatives, systemic anesthetics, alpha-agonists, beta blockers, antihypertensive agents, cardiac glycosides, or systemic anticoagulants. - The subject is currently enrolled in an investigational drug or device study or participated in such a study in the past 3 months prior to enrollment and is still in the exclusion period on the day of the Treatment visit. |
Country | Name | City | State |
---|---|---|---|
United States | Derm Research, Inc | Austin | Texas |
United States | J&S Studies | College Station | Texas |
United States | Philadephia Institute of Dermatology | Fort Washington | Pennsylvania |
United States | Burke Pharmaceutical Research | Hot Springs | Arkansas |
United States | The Education & Research Foundation | Lynchburg | Virginia |
Lead Sponsor | Collaborator |
---|---|
Galderma R&D |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Response Rate for Achieving a 2 Grade Improvement on Clinician's Erythema Assessment (CEA) and Patient Self Assessment (PSA) Over 12 Hours After Dosing. | Baseline and every hour for 12 hours following application |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT03708263 -
Evaluation of the New Laser PHOTOLASE PLV-585nm for the Treatment of Rosacea
|
N/A | |
Completed |
NCT02268474 -
Excel V 532 nm KTP Laser for Treatment of Erythematotelangiectatic Rosacea & Papulopustular Rosacea
|
N/A | |
Completed |
NCT01756027 -
Feasibility Study: Ulthera System for the Treatment of Rosacea
|
N/A | |
Completed |
NCT06331533 -
Intradermal BoNT-A Treatment in Erythematotelangiectatic Rosacea
|
Phase 4 | |
Completed |
NCT02144181 -
Ultherapy® for the Treatment of Erythematotelangiectatic Rosacea
|
N/A | |
Recruiting |
NCT05360251 -
Pulsed Dye Laser and Intense Pulsed Light Configured With Different Wavelength Bands in Improving Erythematotelangiectatic Rosacea
|
N/A | |
Completed |
NCT01045551 -
Open Label Pilot Study of Apremilast in Treatment of Rosacea
|
Phase 2 | |
Completed |
NCT00945373 -
Combination Therapy for the Treatment of Rosacea
|
Phase 1 | |
Completed |
NCT04153188 -
Pulsed Dye Laser Treatment and Oxymetazoline Hydrochloride (HCL) 1% Cream for Erythematotelangiectatic Rosacea
|
Phase 4 | |
Completed |
NCT02393937 -
A Therapeutic Equivalence Study of Two Metronidazole Gel 1% Topical Treatments of Rosacea
|
Phase 3 | |
Completed |
NCT02052999 -
Study to Evaluate the Efficacy and Safety of PAC-14028 Cream in Rosacea Patients
|
Phase 2 |